September 15, 2017

IntraBio Inc. is pleased to announce significant progress in the treatment of rare and neurodegenerative diseases with IB1000, a well-tolerated, modified amino acid that is administered orally. Most notably, IB1000 is showing promising effects in Phase 2 observational clinical studies in patients with Niemann-Pick Type C (NPC) disease, Late-Onset Tay Sachs (LOTS) disease, and different […]

June 1, 2017

IntraBio Ltd, a clinical stage biopharmacuetical company developing treatments for rare lysosomal storage disorders and neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation (EU/3/17/1878) to Ursodeoxycholic Acid (UDCA) for the treatment of Niemann-Pick disease (NPC) Type A, B, and C. “We are pleased to receive orphan designation for UDCA, which […]

April 1, 2017

IntraBio Ltd has announced that it has been granted orphan designation (EU/3/17/1848) by the European Commission on its amino acid analogue-based drug product (IB 1000), for therapeutic use in the rare lysosomal storage disorders Niemann-Pick disease type C and also disease Types A & B. IntraBio, with its collaborators, have completed multiple observational clinical studies […]